Therefore, the use of BTK inhibitors could result in anti-cancer activity not only in hematological malignancies, but also in solid tumors [18,20], both indirectly, via acting on the tumor microenvironment (TME), and directly, by acting on the tumor cells themselves [11,12]. The gene discussed is BTK; the disease is hematologic disorder.